(Q34033259)

30 July 2017

title

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians (English)

1 reference

30 July 2017

0 references

0 references

1 reference

Mehrul Hasnain

1

1 reference

30 July 2017

W Victor R Vieweg

series ordinal

2

1 reference

30 July 2017

Bruce Hollett

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

30 July 2017

published in

Postgraduate Medicine

1 reference

30 July 2017

volume

124

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

154-167

1 reference

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Obesity and severe obesity forecasts through 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

National patterns in antidepressant medication treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Understanding the burden of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Asenapine: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Abnormal glucose metabolism in patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Acute effects of newer antipsychotic drugs on glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Psychotropic drug considerations in depressed patients with metabolic disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Antidepressants and Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effects of Nefazodone on Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

No increased incidence of diabetes in antidepressant users

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Type of antidepressant therapy and risk of type 2 diabetes in people with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Antidepressant use in the absence of common mental disorders in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Proportion of antidepressants prescribed without a psychiatric diagnosis is growing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Off-label prescribing patterns of antidepressants in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Drug-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A clinical study of the association of antipsychotics with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Clozapine-induced severe mixed hyperlipidemia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A review of evidence-based strategies to treat obesity in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

An update on the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

A case series: evaluation of the metabolic safety of aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Impaired fasting glucose and impaired glucose tolerance: implications for care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

Doctor–patient communication about drugs: the evidence for shared decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2577

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.07.2577

1 reference

30 July 2017

1 reference